Specific activation of PDK1 in BRCA2 mutation carriers is interesting as this kinase has recently been shown to confer resistance to CDK4/6 inhibitors in ER+ breast cancer cell lines, and inhibitors targeting this kinase are under development (62). This evidence concerns the gene CDK4 and breast cancer.